Navigation Links
Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
Date:11/11/2011

DURHAM, N.C., Nov. 11, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced a late-breaking poster presentation at the American Society of Nephrology's (ASN) Kidney Week 2011 Annual Meeting being held November 8-13, 2011 in Philadelphia, PA.  

V. Ram Peddi, MD, Transplant Nephrologist and Director of Kidney Transplant Research at California Pacific Medical Center, will present data from Chimerix's Phase 1/2 trial evaluating CMX001 in transplant patients with BK virus (BKV) infection.  The poster presentation, entitled "CMX001 Was Well-Tolerated and Without Nephrotoxicity in Renal Transplant and Hematopoietic Stem Cell Transplant Recipients with BK Virus Infection in a Prospective, Randomized, Double-Blind Study," is part of the "Late-Breaking Clinical Trials Poster" session and begins at 10:00 am on Saturday, November 12 at the Philadelphia Convention Center.

"In the Phase 1/2 trial, CMX001 was generally safe and well tolerated when administered to renal transplant (RT) and hematopoietic stem cell transplant (HSCT) recipients," stated Wendy Painter, MD, MPH, Chief Medical Officer of Chimerix, Inc.  "Importantly, no signs of nephrotoxicity were seen following five weekly oral doses of 40 mg and the pharmacokinetics of CMX001 and cidofovir were similar between kidney transplant and bone marrow transplant recipients."  These findings are consistent with results from other CMX001 clinical trials and based on Chimerix's experience with subjects treated under emergency INDs.

CMX001 is being tested in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, pre-emption and treatment of double-stranded DNA (dsDNA) viruses, including herpesviruses and adenoviruses, and as a potential biodefense countermeasure in the event of a smallpox release.  Data from an ongoing, placebo-controlled Phase 2 clinical trial
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Chimerix to Present at Stifel Nicolaus 2011 Healthcare Conference
2. Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients
3. Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract
4. Chimerix to Present at Two Upcoming Investor Conferences
5. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
6. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
7. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
8. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
9. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
10. Chimerix to Present at Upcoming Investor Conferences
11. Chimerix Initiates Phase 1 Study of CMX157
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Francisco, CA (PRWEB) May 23, 2013 ... who encourage all types of inventions. They focus on ... now noticing this community gravitate toward bringing their ideas ... the DIY Biology Movement, works on making projects using ... the DNA of plants to make them glow with ...
(Date:5/23/2013)... May 23, 2013 VG Energy, an ... with DAK Renewable Research to conduct field trials ... VG Energy is a majority owned subsidiary of ... VG Energy,s exclusively licensed compound LipidMax selectively ... yield in plants, possessing a wide variety of ...
(Date:5/23/2013)... 2013 Virobay, Inc. today announced that their ... an important milestone, as Virobay has now initiated a ... cathepsin S inhibitor.   The first Phase ... study designed to evaluate the safety, tolerability, pharmacokinetics and ... "The initiation of this Phase 1 trial ...
(Date:5/23/2013)... 23, 2013 On April 19th the ... supermarkets to search for the growing antibiotic resistant bacteria ... from a year long study were released late last ... specifically meats, over previous years. For those suffering from ... of antibiotic resistant bacteria in food, may eventually help ...
Breaking Biology Technology:Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2
...   Reprints Desk, Inc., a Derycz Scientific (OTC.BB:DYSC) company, ... features in Bibliogo, the journal article web app that ... to individual users who sign up at www.bibliogo.com ... save time accessing full-text papers from PubMed and ...
... Feb. 2, 2012 Auxogyn, Inc., a privately-held company focused ... the final tranche of its Series A financing, bringing the ... in May 2010, and investors in the round include Kleiner ... "Over the course of the last year, we ...
... Cambrex Corporation (NYSE: CBM ) announced that ... Monday, February 6, 2012 after the market closes. ... to discuss the fourth quarter 2011 financial results.  , ... February 7, 2012 at 8:30 a.m. Eastern Time  Dial-in:1-866-719-0110 ...
Cached Biology Technology:PubMed Users Now Save Time Accessing and Organizing Scientific Papers by Using Bibliogo From Reprints Desk 2PubMed Users Now Save Time Accessing and Organizing Scientific Papers by Using Bibliogo From Reprints Desk 3Auxogyn Completes $20 Million In Series A Funding 2Auxogyn Completes $20 Million In Series A Funding 3
(Date:5/22/2013)... The feared Legionella pneumophila bacteria is responsible ... pneumonia. In order to infect us, this pathogen has ... and go unnoticed in our cells, thus avoiding these ... the Basque biosciences research centre, CIC bioGUNE, in which ... the USA and the National Supercomputation Centre in Barcelona ...
(Date:5/22/2013)... of pollinating insects and wild plants have slowed in ... led by the University of Leeds and the Naturalis ... dramatic reductions in the diversity of species in Britain, ... , But the picture brightened markedly after 1990, with ... bees, hoverflies and wild plants. , Professor ...
(Date:5/21/2013)... a whale entangled in fishing gear, scientists showed for ... diving and swimming behavior. The monitoring revealed how fishing ... their energy as they drag gear for months or ... The scientists in this entanglement response suction-cupped a cellphone-size ... Atlantic right whale called Eg 3911. The Dtag, developed ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3Study reveals how fishing gear can cause slow death of whales 2Study reveals how fishing gear can cause slow death of whales 3
... surviving, growing and reproducing out of control. And signals ... growing or to die. In breast cancer, one tricky ... and sometimes suppressing them. A University of Colorado ... Oncogene details how tumors may flip the TGF-beta ...
... Texas at Austin researchers have demonstrated a new and ... heart and limbs a research advancement that could ... the leading cause of death in the Western world. ... Engineering Assistant Professor Aaron Baker could allow doctors to ...
... This press release is available in German . ... has approved the establishment of four new Research Units. This ... meeting in Bonn. The purpose of the research consortia is ... topical questions in their disciplines and to establish innovative research ...
Cached Biology News:Study details on-off switch that promotes or suppresses breast cancer 2New ability to regrow blood vessels holds promise for treatment of heart disease 2New ability to regrow blood vessels holds promise for treatment of heart disease 3DFG to establish 4 new research units 2DFG to establish 4 new research units 3
ANTI CORTIS BIN GLOB...
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
ANTI S. ENTERID LPS...
... contains the basic components required for the ... and recombinant Feline IL-10 in cell culture ... materials to run ELISAs on approximately fifteen ... are met: The assay is run ...
Biology Products: